Screening of HLA-B*5701 in HIV infected/AIDS patients receiving first line antiretroviral therapy using developed real time PCR
There are some recent reports that the screening of HLA-B*5701 has helped predicting the occurrence of hypersensitivity to abacavir in HIV infected/AIDS patients. The researcher, therefore, developed Real time PCR method for screening of HLA-B*5701 in the HIV infected/AIDS patients to prevent hypers...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Chaing Mai University
2011-09-01
|
Series: | Journal of Associated Medical Sciences |
Subjects: | |
Online Access: | https://www.tci-thaijo.org/index.php/bulletinAMS/article/view/60057 |
id |
doaj-a8ddeab200a8407486dcc3b186b89d85 |
---|---|
record_format |
Article |
spelling |
doaj-a8ddeab200a8407486dcc3b186b89d852020-11-24T21:48:20ZengChaing Mai UniversityJournal of Associated Medical Sciences2539-60562539-60562011-09-0144318818860057Screening of HLA-B*5701 in HIV infected/AIDS patients receiving first line antiretroviral therapy using developed real time PCRPoonsub PalacajornsukSakchai DettrairatTassanee SrivichaiNipapan LeetrakoolWarunee KunachiwaThere are some recent reports that the screening of HLA-B*5701 has helped predicting the occurrence of hypersensitivity to abacavir in HIV infected/AIDS patients. The researcher, therefore, developed Real time PCR method for screening of HLA-B*5701 in the HIV infected/AIDS patients to prevent hypersensitivity to abacavir by collecting the blood samples collected from 147 HIV infected/AIDS patients and first screened for HLA-B17 (HLA-B57 and HLA-B58) by flow cytometry. The results revealed that 22 samples were positive (15%) and 125 samples were negative (85%) for HLA-B17. Then, all of the positive samples were subjected to screening of HLA-B*5701 by the developed Real time PCR. The results revealed that 2 samples were HLA-B*5701 (1.4%). In addition, 88 blood samples of HIV infected/AIDS patients were collected and subjected to screening of HLA-B*5701 by the developed Real time PCR. The results revealed that all of the samples were negative. From this study, 2 samples out of the collected 235 blood samples were HLA-B*5701 positive (0.85%). It can be concluded that the developed Real time PCR can be used for screening HLA-B*5701 which will be useful for planning to prevent the occurrence of hypersensitivity to abacavir before treatment HIV infected/AIDS patients with abacavir.https://www.tci-thaijo.org/index.php/bulletinAMS/article/view/60057HLA-B*5701HIV infected patientsAIDS patientsAntiretrovirusReal time PCR |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Poonsub Palacajornsuk Sakchai Dettrairat Tassanee Srivichai Nipapan Leetrakool Warunee Kunachiwa |
spellingShingle |
Poonsub Palacajornsuk Sakchai Dettrairat Tassanee Srivichai Nipapan Leetrakool Warunee Kunachiwa Screening of HLA-B*5701 in HIV infected/AIDS patients receiving first line antiretroviral therapy using developed real time PCR Journal of Associated Medical Sciences HLA-B*5701 HIV infected patients AIDS patients Antiretrovirus Real time PCR |
author_facet |
Poonsub Palacajornsuk Sakchai Dettrairat Tassanee Srivichai Nipapan Leetrakool Warunee Kunachiwa |
author_sort |
Poonsub Palacajornsuk |
title |
Screening of HLA-B*5701 in HIV infected/AIDS patients receiving first line antiretroviral therapy using developed real time PCR |
title_short |
Screening of HLA-B*5701 in HIV infected/AIDS patients receiving first line antiretroviral therapy using developed real time PCR |
title_full |
Screening of HLA-B*5701 in HIV infected/AIDS patients receiving first line antiretroviral therapy using developed real time PCR |
title_fullStr |
Screening of HLA-B*5701 in HIV infected/AIDS patients receiving first line antiretroviral therapy using developed real time PCR |
title_full_unstemmed |
Screening of HLA-B*5701 in HIV infected/AIDS patients receiving first line antiretroviral therapy using developed real time PCR |
title_sort |
screening of hla-b*5701 in hiv infected/aids patients receiving first line antiretroviral therapy using developed real time pcr |
publisher |
Chaing Mai University |
series |
Journal of Associated Medical Sciences |
issn |
2539-6056 2539-6056 |
publishDate |
2011-09-01 |
description |
There are some recent reports that the screening of HLA-B*5701 has helped predicting the occurrence of hypersensitivity to abacavir in HIV infected/AIDS patients. The researcher, therefore, developed Real time PCR method for screening of HLA-B*5701 in the HIV infected/AIDS patients to prevent hypersensitivity to abacavir by collecting the blood samples collected from 147 HIV infected/AIDS patients and first screened for HLA-B17 (HLA-B57 and HLA-B58) by flow cytometry. The results revealed that 22 samples were positive (15%) and 125 samples were negative (85%) for HLA-B17. Then, all of the positive samples were subjected to screening of HLA-B*5701 by the developed Real time PCR. The results revealed that 2 samples were HLA-B*5701 (1.4%). In addition, 88 blood samples of HIV infected/AIDS patients were collected and subjected to screening of HLA-B*5701 by the developed Real time PCR. The results revealed that all of the samples were negative. From this study, 2 samples out of the collected 235 blood samples were HLA-B*5701 positive (0.85%). It can be concluded that the developed Real time PCR can be used for screening HLA-B*5701 which will be useful for planning to prevent the occurrence of hypersensitivity to abacavir before treatment HIV infected/AIDS patients with abacavir. |
topic |
HLA-B*5701 HIV infected patients AIDS patients Antiretrovirus Real time PCR |
url |
https://www.tci-thaijo.org/index.php/bulletinAMS/article/view/60057 |
work_keys_str_mv |
AT poonsubpalacajornsuk screeningofhlab5701inhivinfectedaidspatientsreceivingfirstlineantiretroviraltherapyusingdevelopedrealtimepcr AT sakchaidettrairat screeningofhlab5701inhivinfectedaidspatientsreceivingfirstlineantiretroviraltherapyusingdevelopedrealtimepcr AT tassaneesrivichai screeningofhlab5701inhivinfectedaidspatientsreceivingfirstlineantiretroviraltherapyusingdevelopedrealtimepcr AT nipapanleetrakool screeningofhlab5701inhivinfectedaidspatientsreceivingfirstlineantiretroviraltherapyusingdevelopedrealtimepcr AT waruneekunachiwa screeningofhlab5701inhivinfectedaidspatientsreceivingfirstlineantiretroviraltherapyusingdevelopedrealtimepcr |
_version_ |
1725892811941740544 |